NeuroPace's RNS System trial showed a strong safety profile and subgroup efficacy in drug-resistant epilepsy, prompting FDA ...

Shares of NeuroPace sank after the company said the study of its RNS system for treating drug-resistant idiopathic generalized epilepsy missed a primary endpoint. The stock was down 37% at $11.15 in ...

"We view the totality of the data in the NAUTILUS study as a meaningful catalyst that adds to the growing body of evidence and momentum in our business,” said Joel Becker, Chief Executive Officer.

The bill safeguards physician-directed care in a school setting and helps school personnel manage students living with ...

Ukraine says ready to meet Russia but wants peace terms in advance Following its successful US launch and FDA clearance, Empatica is proud to announce that EpiMonitor, its pioneering epilepsy ...

HealthDay News — For patients with diffuse gliomas, tumor-related epilepsy (TRE) is not a strong prognostic factor, according to a study published in the May issue of Brain and Behavior.

A new study suggests that gabapentin, a widely used anti-seizure medication, may improve survival in patients with ...